Histone deacetylase inhibitors: clinical implications for hematological malignancies
Authors:
- Francesco Paolo TambaroFTFrancesco Paolo Tambaro
- Carmela Dell’aversanaCDCarmela Dell’aversana
- Vincenzo CarafaVincenzo Carafa
- Angela NebbiosoANAngela Nebbioso
- Branka RadicBRBranka Radic
- Felicetto FerraraFFFelicetto Ferrara
- Lucia AltucciLucia Altucci
Open Access
- 28 July 2010
- journal article
- review article
- Published by Springer Nature in Clinical Epigenetics
- Vol. 1 (1-2) , 25-44
Abstract
Histone modifications have widely been implicated in cancer development and progression and are potentially reversible by drug treatments. The N-terminal tails of each histone extend outward through the DNA strand containing amino acid residues modified by posttranslational acetylation, methylation, and phosphorylation. These modifications change the secondary structure of the histone protein tails in relation to the DNA strands, increasing the distance between DNA and histones, and thus allowing accessibility of transcription factors to gene promoter regions. A large number of HDAC inhibitors have been synthesized in the last few years, most being effective in vitro, inducing cancer cells differentiation or cell death. The majority of the inhibitors are in clinical trials, unlike the suberoylanilide hydroxamic acid, a pan-HDACi, and Romidepsin (FK 228), a class I-selective HDACi, which are only approved in the second line treatment of refractory, persistent or relapsed cutaneous T-cell lymphoma, and active in approximately 150 clinical trials, in monotherapy or in association. Preclinical studies investigated the use of these drugs in clinical practice, as single agents and in combination with chemotherapy, hypomethylating agents, proteasome inhibitors, and MTOR inhibitors, showing a significant effect mostly in hematological malignancies. The aim of this review is to focus on the biological features of these drugs, analyzing the possible mechanism(s) of action and outline an overview on the current use in the clinical practice.Keywords
This publication has 105 references indexed in Scilit:
- HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapyProceedings of the National Academy of Sciences, 2010
- Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T‐cell lymphomaBritish Journal of Haematology, 2009
- Functional Connection between Deimination and Deacetylation of HistonesMolecular and Cellular Biology, 2009
- Enzymes in the NAD+ Salvage Pathway Regulate SIRT1 Activity at Target Gene PromotersJournal of Biological Chemistry, 2009
- A Gene Signature-Based Approach Identifies mTOR as a Regulator of p73Molecular and Cellular Biology, 2008
- Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysisThe Lancet Oncology, 2008
- R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignanciesBritish Journal of Cancer, 2007
- Recruitment of the SWI/SNF protein Brg1 by a multiprotein complex effects transcriptional repression in murine erythroid progenitorsBiochemical Journal, 2006
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Epigenetic therapy of cancer: past, present and futureNature Reviews Drug Discovery, 2006